Blueprint Medicines Corporation Company Profile (NASDAQ:BPMC)

About Blueprint Medicines Corporation

Blueprint Medicines Corporation logoBlueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company's drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BPMC
  • CUSIP:
Key Metrics:
  • Previous Close: $36.05
  • 50 Day Moving Average: $33.36
  • 200 Day Moving Average: $29.89
  • 52-Week Range: $13.27 - $38.33
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.99
  • P/E Growth: 0.00
  • Market Cap: $969.17M
  • Outstanding Shares: 27,293,000
  • Beta: 1.44
Profitability:
  • Net Margins: -270.30%
  • Return on Equity: -55.22%
  • Return on Assets: -36.15%
Debt:
  • Debt-to-Equity Ratio: 0.05%
  • Current Ratio: 6.54%
  • Quick Ratio: 6.54%
Additional Links:
Companies Related to Blueprint Medicines Corporation:

Analyst Ratings

Consensus Ratings for Blueprint Medicines Corporation (NASDAQ:BPMC) (?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $34.24 (3.57% downside)

Analysts' Ratings History for Blueprint Medicines Corporation (NASDAQ:BPMC)
Show:
DateFirmActionRatingPrice TargetDetails
2/15/2017Morgan StanleyInitiated CoverageOverweight$45.00View Rating Details
12/14/2016Jefferies Group LLCInitiated CoverageBuy$40.00View Rating Details
12/6/2016WedbushReiterated RatingOutperform$43.00View Rating Details
12/5/2016Cowen and CompanyReiterated RatingBuy$38.33 -> $33.19View Rating Details
12/1/2016JMP SecuritiesReiterated RatingBuyView Rating Details
11/12/2016Canaccord GenuitySet Price TargetBuy$35.00View Rating Details
5/27/2016Raymond James Financial, Inc.Initiated CoverageOutperform$23.00View Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$54.00 -> $37.00View Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$26.00 -> $15.00View Rating Details
(Data available from 2/21/2015 forward)

Earnings

Earnings History for Blueprint Medicines Corporation (NASDAQ:BPMC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2017        
11/10/2016Q316($0.79)($0.62)$6.06 million$6.16 millionViewListenView Earnings Details
8/9/2016Q216($0.73)($0.70)$4.41 million$7.07 millionViewListenView Earnings Details
5/10/2016Q116($0.70)($0.57)$3.24 million$6.90 millionViewListenView Earnings Details
3/11/2016Q415($0.53)($0.58)$2.85 million$4.64 millionViewN/AView Earnings Details
11/9/2015Q3($0.54)($0.47)$1.83 million$3.43 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Blueprint Medicines Corporation (NASDAQ:BPMC)
Current Year EPS Consensus Estimate: $-2.71 EPS
Next Year EPS Consensus Estimate: $-3.95 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.82)($0.82)($0.82)
Q3 20161($0.77)($0.77)($0.77)
Q4 20162($0.68)($0.68)($0.68)
Q1 20172($0.76)($0.73)($0.75)
Q2 20172($0.84)($0.81)($0.83)
Q3 20172($0.98)($0.96)($0.97)
Q4 20172($1.17)($1.12)($1.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Blueprint Medicines Corporation (NASDAQ:BPMC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Blueprint Medicines Corporation (NASDAQ:BPMC)
Insider Ownership Percentage: 3.93%
Institutional Ownership Percentage: 59.51%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell1,000,000$35.28$35,280,000.00View SEC Filing  
12/19/2016Kevin P. StarrMajor ShareholderSell106,489$28.19$3,001,924.91View SEC Filing  
12/1/2016Daniel LynchDirectorSell200$30.02$6,004.00View SEC Filing  
10/13/2016Daniel LynchDirectorSell21,800$30.02$654,436.00View SEC Filing  
8/8/2016Jeffrey W AlbersCEOSell17,000$22.86$388,620.00View SEC Filing  
6/3/2016Jeffrey W AlbersCEOSell17,000$20.03$340,510.00View SEC Filing  
4/13/2016Christoph LengauerInsiderSell15,872$20.01$317,598.72View SEC Filing  
4/12/2016Christoph LengauerInsiderSell18,853$20.14$379,699.42View SEC Filing  
4/6/2016Jeffrey W AlbersCEOSell17,000$20.42$347,140.00View SEC Filing  
12/17/2015Christoph LengauerinsiderSell31,119$25.05$779,530.95View SEC Filing  
11/27/2015Fmr LlcInsiderSell287,415$21.48$6,173,674.20View SEC Filing  
11/24/2015Fmr LlcInsiderSell161,271$20.14$3,247,997.94View SEC Filing  
11/23/2015Fmr LlcInsiderSell189,572$20.15$3,819,875.80View SEC Filing  
11/19/2015Fmr LlcInsiderSell237,218$19.76$4,687,427.68View SEC Filing  
11/17/2015Fmr LlcInsiderSell27,490$20.60$566,294.00View SEC Filing  
11/3/2015Christoph LengauerinsiderSell84,998$21.05$1,789,207.90View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Blueprint Medicines Corporation (NASDAQ:BPMC)
DateHeadline
finance.yahoo.com logoCoverage initiated on Blueprint Medicines by Morgan Stanley (NASDAQ:BPMC)
finance.yahoo.com - February 16 at 8:51 AM
finance.yahoo.com logoBlueprint Medicines to Present at 2017 RBC Capital Markets Global Healthcare Conference (NASDAQ:BPMC)
finance.yahoo.com - February 16 at 8:51 AM
News IconEquity Focus: Looking at Shares of Blueprint Medicines Corporation (NASDAQ:BPMC) - Davidson Register (NASDAQ:BPMC)
davidsonregister.com - February 13 at 9:36 PM
News IconShares of Blueprint Medicines Corporation (BPMC) Sees Large Outflow of Money - Highland Mirror (NASDAQ:BPMC)
www.highlandmirror.com - February 10 at 3:32 PM
News IconBlueprint Medicines Corp BPMC Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:BPMC)
www.bioportfolio.com - February 7 at 10:03 PM
nasdaq.com logoTaylor Investment Counselors Llc Buys Kinder Morgan, Crestwood Equity Partners LP, Surgical ... (NASDAQ:BPMC)
www.nasdaq.com - February 3 at 4:10 PM
finance.yahoo.com logoMead Johnson (MJN) Q4 Earnings: Disappointment in Store? (NASDAQ:BPMC)
finance.yahoo.com - February 1 at 9:16 PM
finance.yahoo.com logoResMed (RMD) Q2 Earnings: Disappointment in the Cards? (NASDAQ:BPMC)
finance.yahoo.com - January 13 at 4:42 PM
finance.yahoo.com logoAnalyst: Government wouldn't want to kill goose that lays... (NASDAQ:BPMC)
finance.yahoo.com - January 11 at 4:24 PM
capitalcube.com logoBlueprint Medicines Corp. – Value Analysis (NASDAQ:BPMC) : January 9, 2017 (NASDAQ:BPMC)
www.capitalcube.com - January 9 at 5:05 PM
capitalcube.com logoBlueprint Medicines Corp. breached its 50 day moving average in a Bullish Manner : BPMC-US : January 6, 2017 (NASDAQ:BPMC)
us.rd.yahoo.com - January 7 at 2:32 AM
finance.yahoo.com logoBlueprint Medicines (BPMC) Shares March Higher, Can It Continue? (NASDAQ:BPMC)
finance.yahoo.com - January 6 at 4:21 PM
zacks.com logoNew Strong Buy Stocks for December 28th (NASDAQ:BPMC)
www.zacks.com - December 28 at 9:00 PM
finance.yahoo.com logoBlueprint Medicines (BPMC): Strong Industry, Solid Earnings Estimate Revisions (NASDAQ:BPMC)
finance.yahoo.com - December 23 at 4:08 PM
News IconInteresting BPMC Put And Call Options For February 2017 (NASDAQ:BPMC)
www.stockoptionschannel.com - December 21 at 3:35 AM
us.rd.yahoo.com logoCoverage initiated on Blueprint Medicines by Jefferies (NASDAQ:BPMC)
us.rd.yahoo.com - December 14 at 9:43 PM
seekingalpha.com logoBlueprint Medicines: A Nascent Leader In Targeted Oncology (NASDAQ:BPMC)
seekingalpha.com - December 14 at 4:43 PM
finance.yahoo.com logoBlueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock (NASDAQ:BPMC)
finance.yahoo.com - December 13 at 4:39 PM
marketexclusive.com logoBlueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:BPMC)
marketexclusive.com - December 12 at 10:53 AM
News IconBlueprint Medicines Corp Announces Proposed Public Offering of Shares of Common Stock (NASDAQ:BPMC)
flapship.com - December 10 at 11:50 AM
News IconThe Blueprint Medicines Corp. (BPMC) Rating Reiterate by Cowen and Company (NASDAQ:BPMC)
myhealthbowl.com - December 10 at 11:50 AM
News IconAnalysts Update Their Price Target On Blueprint Medicines Corporation (NASDAQ:BPMC) (NASDAQ:BPMC)
canalcncarauca.com - December 10 at 11:50 AM
News IconThe Blueprint Medicines Corp. (BPMC) to Release Earnings on Thursday (NASDAQ:BPMC)
larampadinapoli.com - December 10 at 11:50 AM
biz.yahoo.com logoBLUEPRINT MEDICINES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stat (NASDAQ:BPMC)
biz.yahoo.com - December 8 at 9:12 PM
streetinsider.com logoBlueprint Medicines (BPMC) Prices $125M Common Stock Offering (NASDAQ:BPMC)
www.streetinsider.com - December 8 at 4:09 PM
finance.yahoo.com logoBlueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock (NASDAQ:BPMC)
finance.yahoo.com - December 7 at 9:40 PM
finance.yahoo.com logoBlueprint Medicines Announces Proposed Public Offering of Shares of Common Stock (NASDAQ:BPMC)
finance.yahoo.com - December 6 at 9:21 PM
smarteranalyst.com logoCompany Update (NASDAQ:BPMC): Blueprint Medicines Corp Announces Proposed Public Offering of Shares of Common Stock (NASDAQ:BPMC)
www.smarteranalyst.com - December 6 at 9:21 PM
us.rd.yahoo.com logoBlueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis (NASDAQ:BPMC)
us.rd.yahoo.com - December 5 at 4:48 PM
News IconBlueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic... (NASDAQ:BPMC)
ih.advfn.com - December 5 at 11:13 AM
biz.yahoo.com logoBlueprint Medicines Conference Call, ASH Annual Meeting & Expedition scheduled for 8:00 am ET today (NASDAQ:BPMC)
biz.yahoo.com - December 5 at 11:13 AM
rttnews.com logoRio Tinto: SEC Investigation Remains Ongoing Relating To Coal Mozambique (NASDAQ:BPMC)
www.rttnews.com - December 1 at 4:03 PM
marketexclusive.com logoBlueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Other Events (NASDAQ:BPMC)
marketexclusive.com - December 1 at 4:03 PM
capitalcube.com logoETFs with exposure to Blueprint Medicines Corp. : December 1, 2016 (NASDAQ:BPMC)
www.capitalcube.com - December 1 at 4:03 PM
biz.yahoo.com logoBlueprint Medicines Corp EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Call scheduled for 12:30 pm ET today (NASDAQ:BPMC)
biz.yahoo.com - December 1 at 4:03 PM
nasdaq.com logoIt's All Green For BLUE, HTBX Plunges On Failed Study, Watch Out For BPMC (NASDAQ:BPMC)
www.nasdaq.com - December 1 at 2:01 AM
News IconBlueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastroin... (NASDAQ:BPMC)
ih.advfn.com - December 1 at 2:01 AM
us.rd.yahoo.com logoBlueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors (NASDAQ:BPMC)
us.rd.yahoo.com - November 30 at 9:00 PM
us.rd.yahoo.com logo6:04 pm Blueprint Medicines announces proof-of-concept data from Ph 1 trial of BLU-285 in patients with advanced gastrointestinal stromal tumors -- tumor reduction observed in both PDGFR-driven and KIT-driven patients (NASDAQ:BPMC)
us.rd.yahoo.com - November 30 at 9:00 PM
capitalcube.com logoBlueprint Medicines Corp. breached its 50 day moving average in a Bearish Manner : BPMC-US : November 30, 2016 (NASDAQ:BPMC)
www.capitalcube.com - November 30 at 4:00 PM
streetinsider.com logoForm 8-K Blueprint Medicines Corp For: Nov 28 (NASDAQ:BPMC)
www.streetinsider.com - November 30 at 6:09 AM
News IconBlueprint Medicines Announces Proof-of-Concept Data from Global Phase 1 Clinical Trial of BLU-554 in Patients with Advanced H... (NASDAQ:BPMC)
ih.advfn.com - November 30 at 6:09 AM
4-traders.com logoBlueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD Disclosure (NASDAQ:BPMC)
www.4-traders.com - November 30 at 6:09 AM
finance.yahoo.com logoBlueprint Medicines Announces Proof-of-Concept Data from Global Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma (NASDAQ:BPMC)
finance.yahoo.com - November 30 at 6:09 AM
biz.yahoo.com logoBLUEPRINT MEDICINES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:BPMC)
biz.yahoo.com - November 30 at 6:09 AM
News IconBlueprint Medicines Corporation BPMC Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:BPMC)
www.bioportfolio.com - November 19 at 3:56 PM
capitalcube.com logoBlueprint Medicines Corp. :BPMC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016 (NASDAQ:BPMC)
www.capitalcube.com - November 18 at 12:52 PM
4-traders.com logoBLUEPRINT MEDICINES CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) (NASDAQ:BPMC)
www.4-traders.com - November 15 at 12:39 PM
publicnow.com logoBlueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trials for BLU-285 and BLU-554 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (NASDAQ:BPMC)
www.publicnow.com - November 15 at 12:39 PM
finance.yahoo.com logo4:04 pm Blueprint Medicines announces that Marion Dorsch, Ph.D., will succeed Christoph Lengauer, Ph.D., MBA, as Chief Scientific Officer, effective November 21 (NASDAQ:BPMC)
finance.yahoo.com - November 14 at 9:00 PM

Social

What is Blueprint Medicines Corporation's stock symbol?

Blueprint Medicines Corporation trades on the NASDAQ under the ticker symbol "BPMC."

Where is Blueprint Medicines Corporation's stock going? Where will Blueprint Medicines Corporation's stock price be in 2017?

8 equities research analysts have issued twelve-month price targets for Blueprint Medicines Corporation's shares. Their forecasts range from $15.00 to $45.00. On average, they expect Blueprint Medicines Corporation's share price to reach $34.24 in the next year.

When will Blueprint Medicines Corporation announce their earnings?

Blueprint Medicines Corporation is scheduled to release their next quarterly earnings announcement on Thursday, March, 9th 2017.

What are analysts saying about Blueprint Medicines Corporation stock?

Here are some recent quotes from research analysts about Blueprint Medicines Corporation stock:

  • According to Zacks Investment Research, "Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA. " (2/7/2017)

  • Jefferies Group LLC analysts commented, "Utilizing its drug discovery platform, BPMC is well positioned to build a balanced pipeline of proprietary & partnered products for cancer/rare disease. Early Ph1 data suggests its two candidates (BLU-285 & BLU-554) are effective & differentiated from current limited tx options, supporting further development." (12/14/2016)

  • Cowen and Company analysts commented, "We are encouraged by the early efficacy seen following BLU-285 administration. BLU-285 has clear activity as evidenced by the observed reductions in serum tryptase and mast cell burden. Safety and tolerability were also good, and provide much room for further dose escalation. We note that BLU-285 has been shown to be safe and well tolerated at doses up to 400mg in GIST, and that dose escalation and longer-term follow up in SM will likely be associated with even more substantial benefit. While it remains to be seen how BLU-285’s profile might stack up relative to other kinase inhibitors including NVS’s midostaurin (pending FDA approval for SM), we expect that more selective and potent inhibition of c-KIT will translate into clinical advantages. We believe advanced SM could represent a >$500MM WW opportunity for BLU-285." (12/5/2016)

Who owns Blueprint Medicines Corporation stock?

Blueprint Medicines Corporation's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (14.21%), Deerfield Management Co. (6.75%), Boxer Capital LLC (2.58%), Sandia Holdings LLC (2.57%), State Street Corp (2.50%) and Foresite Capital Management III LLC (1.10%). Company insiders that own Blueprint Medicines Corporation stock include Christoph Lengauer, Daniel Lynch, Fmr Llc, Jeffrey W Albers, Kevin P Starr and Rock Ventures Ii LP Third.

Who sold Blueprint Medicines Corporation stock? Who is selling Blueprint Medicines Corporation stock?

Blueprint Medicines Corporation's stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, FMR LLC, Allianz Asset Management AG and Renaissance Technologies LLC. Company insiders that have sold Blueprint Medicines Corporation stock in the last year include Christoph Lengauer, Daniel Lynch, Jeffrey W Albers, Kevin P Starr and Rock Ventures Ii LP Third.

Who bought Blueprint Medicines Corporation stock? Who is buying Blueprint Medicines Corporation stock?

Blueprint Medicines Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Deerfield Management Co., Sandia Holdings LLC, State Street Corp, Foresite Capital Management III LLC, Perceptive Advisors LLC, Franklin Resources Inc., Alyeska Investment Group L.P. and Tudor Investment Corp Et Al.

How do I buy Blueprint Medicines Corporation stock?

Shares of Blueprint Medicines Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Blueprint Medicines Corporation stock cost?

One share of Blueprint Medicines Corporation stock can currently be purchased for approximately $35.51.

Blueprint Medicines Corporation (NASDAQ:BPMC) Chart for Tuesday, February, 21, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Earnings History Chart

Earnings by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Dividend History Chart

Dividend Payments by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Last Updated on 2/21/2017 by MarketBeat.com Staff